Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.42 |
| ▸ | LCK | P06239 | 7/20 | 0.42 |
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510431 | 0.92 | EGFR (0.39) | SRCLCKKDRFGFR1EGFR | |
| SCHEMBL8514403 | 0.92 | LCK (0.41) | SRCLCKKDRFGFR1EGFR | |
| SCHEMBL213088 | 0.89 | SRC (0.49) | SRCLCKKDRFGFR1EGFR | |
| SCHEMBL9609439 | 0.89 | SRC (0.43) | SRCLCKKDRFGFR1EGFR | |
| SCHEMBL8511945 | 0.86 | SRC (0.48) | SRCLCKKDRFGFR1EGFR | |
| SCHEMBL8509293 | 0.82 | WEE1 (0.40) | SRCLCKKDREGFRWEE1 | |
| SCHEMBL8510013 | 0.81 | WEE1 (0.38) | SRCLCKKDRFGFR1EGFR | |
| SCHEMBL188629 | 0.81 | WEE1 (0.40) | EGFRWEE1 | |
| SCHEMBL9609438 | 0.80 | SRC (0.41) | SRCLCKKDRFGFR1EGFR | |
| SCHEMBL8514337 | 0.80 | WEE1 (0.38) | EGFRWEE1TNK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | SRC 546/4885LCK 540/4885KDR 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.